Home/Filings/4/A/0000899243-21-028984
4/A//SEC Filing

BINGHAM KATE 4/A

Accession 0000899243-21-028984

CIK 0001761612other

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:17 PM ET

Size

12.6 KB

Accession

0000899243-21-028984

Insider Transaction Report

Form 4/AAmended
Period: 2021-07-13
BINGHAM KATE
Director
Transactions
  • Sale

    Ordinary Shares

    2021-07-13$33.50/sh588$19,6981,875,049 total(indirect: By SV Life Sciences Fund V, L.P.)
  • Sale

    Ordinary Shares

    2021-07-13$33.50/sh12$40239,625 total(indirect: By SV Life Sciences Fund V Strategic Partners, L.P.)
  • Sale

    Ordinary Shares

    2021-07-14$34.01/sh43,378$1,475,1821,831,671 total(indirect: By SV Life Sciences Fund V, L.P.)
  • Sale

    Ordinary Shares

    2021-07-14$34.01/sh917$31,18538,708 total(indirect: By SV Life Sciences Fund V Strategic Partners, L.P.)
Footnotes (4)
  • [F1]These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
  • [F2]These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
  • [F3]These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
  • [F4]These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

Issuer

BICYCLE THERAPEUTICS plc

CIK 0001761612

Entity typeother

Related Parties

1
  • filerCIK 0001185040

Filing Metadata

Form type
4/A
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 4:17 PM ET
Size
12.6 KB